← All trials
NCT01436396
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2011
- Primary completion
- Sep 1, 2013
- Completion date
- Mar 1, 2014
- First posted
- —
- Last posted
- —
- Enrollment
- 792
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
Drugs studied
- pneumococcal 13-valent conjugate vaccine
- hepatitis a vaccine, inactivated
- live, attenuated, dengue serotype 1, 2, 3, 4 virus
- measles, mumps, and rubella vaccine
- haemophilus influenzae type b conjugate vaccine
- acellular pertussis vaccine (including diptheria and tetanus toxoids)
- Bivalent group A and C meningococcal vaccine
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.